Trial record 1 of 1 for:    A8081005
Previous Study | Return to List | Next Study

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00932451
First received: June 30, 2009
Last updated: September 9, 2014
Last verified: September 2014
  Purpose

This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066.


Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Drug: PF-02341066
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Non-Small Cell Lung Cancer Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Objective Response Rate [ Time Frame: 30 months ] [ Designated as safety issue: No ]
  • Type, incidence, severity, seriousness and relationship to study medication of adverse events and laboratory test abnormalities [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Duration of Response [ Time Frame: 30 months ] [ Designated as safety issue: No ]
  • Disease Control Rate [ Time Frame: 30 months ] [ Designated as safety issue: No ]
  • Overall Survival [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]
  • Patient reported symptoms of lung cancer and health-related quality of life [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]
  • Plasma concentrations of PF-02341066 [ Time Frame: 30 months ] [ Designated as safety issue: No ]
  • Types of EML4-ALK fusion variants and ALK gene expression [ Time Frame: 30 months ] [ Designated as safety issue: No ]
  • Protein expression of identified biomarkers in serial tumor samples (when available) [ Time Frame: 30 months ] [ Designated as safety issue: No ]
  • Progression Free Survival [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]
  • Time to Tumor Response [ Time Frame: 30 months ] [ Designated as safety issue: No ]
  • QTc [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]
  • genotypes of alleles possibly associated with adverse hepatic or renal drug reactions [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 1100
Study Start Date: January 2010
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PF-0231066 Drug: PF-02341066
PF-02341066, 250 mg BID, will be administered orally on a continuous schedule

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • histologically or cytologically proven diagnosis of non-small cell lung cancer
  • positive for the ALK fusion gene (test provided by either a central laboratory. Local laboratory may be used for certain cases)
  • may have received pemetrexed or docetaxel from previous Phase 3 trial (A8081007) and discontinued treatment due to Response Evaluation Criterion in Solid Tumors (RECIST)-defined progression. or, once the primary endpoint of Study A8081007 has been analyzed and the results made available, at any time without RECIST-defined progression.
  • Tumors can be measurable or non measurable

Exclusion Criteria:

  • prior treatment with PF-02341066
  • received no prior systemic treatment, chemotherapy or EGFR tyrosine kinase inhibitor, for advanced non-small cell lung cancer
  • current enrollment in another therapeutic clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00932451

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021

  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site Recruiting
Birmingham, Alabama, United States, 35233
Pfizer Investigational Site Recruiting
Birmingham, Alabama, United States, 35294
United States, Arkansas
Pfizer Investigational Site Completed
Little Rock, Arkansas, United States, 72205
United States, California
Pfizer Investigational Site Recruiting
Bakersfield, California, United States, 93309
Pfizer Investigational Site Recruiting
Beverly Hills, California, United States, 90211-1850
Pfizer Investigational Site Recruiting
Beverly Hills, California, United States, 90211
Pfizer Investigational Site Recruiting
La Jolla, California, United States, 92037
Pfizer Investigational Site Recruiting
La Jolla, California, United States, 92093-0698
Pfizer Investigational Site Recruiting
Los Angeles, California, United States, 90095
Pfizer Investigational Site Recruiting
Los Angeles, California, United States, 90095-6984
Pfizer Investigational Site Recruiting
Orange, California, United States, 92868-3298
Pfizer Investigational Site Completed
Palo Alto, California, United States, 94305
Pfizer Investigational Site Recruiting
Sacramento, California, United States, 95817
Pfizer Investigational Site Recruiting
San Diego, California, United States, 92103
Pfizer Investigational Site Recruiting
Santa Monica, California, United States, 90404
Pfizer Investigational Site Terminated
Santa Rosa, California, United States, 95403
United States, Colorado
Pfizer Investigational Site Recruiting
Aurora, Colorado, United States, 80045
Pfizer Investigational Site Recruiting
Denver, Colorado, United States, 80205
Pfizer Investigational Site Recruiting
Lafayette, Colorado, United States, 80026
United States, Connecticut
Pfizer Investigational Site Recruiting
New Haven, Connecticut, United States, 06519
Pfizer Investigational Site Recruiting
New Haven, Connecticut, United States, 06520
Pfizer Investigational Site Recruiting
New Haven, Connecticut, United States, 06510
United States, Florida
Pfizer Investigational Site Terminated
Fort Lauderdale, Florida, United States, 33308
Pfizer Investigational Site Completed
Hollywood, Florida, United States, 33021
Pfizer Investigational Site Completed
Lake Worth, Florida, United States, 33461
Pfizer Investigational Site Completed
Pembroke Pines, Florida, United States, 33028
Pfizer Investigational Site Recruiting
Tampa, Florida, United States, 33612
United States, Georgia
Pfizer Investigational Site Recruiting
Atlanta, Georgia, United States, 30308
Pfizer Investigational Site Completed
Atlanta, Georgia, United States, 30341
Pfizer Investigational Site Recruiting
Atlanta, Georgia, United States, 30322
Pfizer Investigational Site Terminated
Augusta, Georgia, United States, 30912
Pfizer Investigational Site Completed
Decatur, Georgia, United States, 30033
Pfizer Investigational Site Completed
Macon, Georgia, United States, 31217
Pfizer Investigational Site Completed
Marietta, Georgia, United States, 30060
Pfizer Investigational Site Completed
Sandy Springs, Georgia, United States, 30342
United States, Hawaii
Pfizer Investigational Site Terminated
Honolulu, Hawaii, United States, 96817
Pfizer Investigational Site Terminated
Honolulu, Hawaii, United States, 96813
United States, Illinois
Pfizer Investigational Site Recruiting
Chicago, Illinois, United States, 60637
Pfizer Investigational Site Recruiting
Chicago, Illinois, United States, 60612
Pfizer Investigational Site Terminated
Harvey, Illinois, United States, 60426
Pfizer Investigational Site Terminated
Tinley Park, Illinois, United States, 60477
United States, Indiana
Pfizer Investigational Site Recruiting
Indianapolis, Indiana, United States, 46202
Pfizer Investigational Site Recruiting
Indianopolis, Indiana, United States, 46290
Pfizer Investigational Site Terminated
Munster, Indiana, United States, 46321
United States, Maryland
Pfizer Investigational Site Completed
Baltimore, Maryland, United States, 21231
Pfizer Investigational Site Recruiting
Bethesda, Maryland, United States, 20892
United States, Massachusetts
Pfizer Investigational Site Recruiting
Boston, Massachusetts, United States, 02114
Pfizer Investigational Site Recruiting
Boston, Massachusetts, United States, 02115
Pfizer Investigational Site Recruiting
Boston, Massachusetts, United States, 02215
United States, Michigan
Pfizer Investigational Site Recruiting
Detroit, Michigan, United States, 48201
Pfizer Investigational Site Recruiting
Farmington Hills, Michigan, United States, 48334
United States, Missouri
Pfizer Investigational Site Recruiting
Creve Coeur, Missouri, United States, 63141
Pfizer Investigational Site Recruiting
St. Louis, Missouri, United States, 63110-1094
Pfizer Investigational Site Recruiting
St. Louis, Missouri, United States, 63110
Pfizer Investigational Site Recruiting
St. Peters, Missouri, United States, 63376
United States, Nebraska
Pfizer Investigational Site Recruiting
Omaha, Nebraska, United States, 68198-7680
United States, New Hampshire
Pfizer Investigational Site Recruiting
Lebanon, New Hampshire, United States, 03756-0001
United States, New Mexico
Pfizer Investigational Site Completed
Albuquerque, New Mexico, United States, 87106
Pfizer Investigational Site Completed
Albuquerque, New Mexico, United States, 87131
United States, New York
Pfizer Investigational Site Recruiting
Lake Success, New York, United States, 11042
Pfizer Investigational Site Recruiting
Manhasset, New York, United States, 11030
Pfizer Investigational Site Recruiting
New Hyde Park, New York, United States, 11040
Pfizer Investigational Site Recruiting
New York, New York, United States, 10032
Pfizer Investigational Site Recruiting
New York, New York, United States, 10022
Pfizer Investigational Site Recruiting
New York, New York, United States, 10065
Pfizer Investigational Site Completed
Oneida, New York, United States, 13421
Pfizer Investigational Site Completed
Oswego, New York, United States, 13126
Pfizer Investigational Site Completed
Syracuse, New York, United States, 13210
Pfizer Investigational Site Completed
Syracuse, New York, United States, 13210-2306
United States, North Carolina
Pfizer Investigational Site Recruiting
Chapel Hill, North Carolina, United States, 27514
Pfizer Investigational Site Recruiting
Chapel Hill, North Carolina, United States, 27599-7600
Pfizer Investigational Site Completed
Charlotte, North Carolina, United States, 28204
Pfizer Investigational Site Completed
Huntersville, North Carolina, United States, 28078
Pfizer Investigational Site Completed
Matthews, North Carolina, United States, 28105
United States, Ohio
Pfizer Investigational Site Recruiting
Cleveland, Ohio, United States, 44195
Pfizer Investigational Site Recruiting
Columbus, Ohio, United States, 43221
Pfizer Investigational Site Recruiting
Columbus, Ohio, United States, 43205
Pfizer Investigational Site Recruiting
Columbus, Ohio, United States, 43210
United States, Oregon
Pfizer Investigational Site Terminated
Beaverton, Oregon, United States, 97006
Pfizer Investigational Site Terminated
Gresham, Oregon, United States, 97030
Pfizer Investigational Site Terminated
Portland, Oregon, United States, 97216
Pfizer Investigational Site Terminated
Portland, Oregon, United States, 97210
Pfizer Investigational Site Terminated
Portland, Oregon, United States, 97239
Pfizer Investigational Site Terminated
Tualatin, Oregon, United States, 97062
United States, Pennsylvania
Pfizer Investigational Site Terminated
Hershey, Pennsylvania, United States, 17033-0850
Pfizer Investigational Site Recruiting
Philadelphia, Pennsylvania, United States, 19111
Pfizer Investigational Site Recruiting
Philadelphia, Pennsylvania, United States, 19104
Pfizer Investigational Site Completed
Pittsburgh, Pennsylvania, United States, 15232
United States, Rhode Island
Pfizer Investigational Site Terminated
East Providence, Rhode Island, United States, 02915
Pfizer Investigational Site Terminated
East Providence, Rhode Island, United States, 02914
United States, South Carolina
Pfizer Investigational Site Completed
Charleston, South Carolina, United States, 29425
United States, Tennessee
Pfizer Investigational Site Completed
Dickson, Tennessee, United States, 37055
Pfizer Investigational Site Completed
Franklin, Tennessee, United States, 37067
Pfizer Investigational Site Completed
Gallatin, Tennessee, United States, 37066
Pfizer Investigational Site Completed
Hermitage, Tennessee, United States, 37076
Pfizer Investigational Site Completed
Lebanon, Tennessee, United States, 37087
Pfizer Investigational Site Completed
Murfreesboro, Tennessee, United States, 37130
Pfizer Investigational Site Completed
Nashville, Tennessee, United States, 37205
Pfizer Investigational Site Completed
Nashville, Tennessee, United States, 37211
Pfizer Investigational Site Completed
Nashville, Tennessee, United States, 37207
Pfizer Investigational Site Recruiting
Nashville, Tennessee, United States, 37232-5536
Pfizer Investigational Site Completed
Nashville, Tennessee, United States, 37203
Pfizer Investigational Site Recruiting
Nashville, Tennessee, United States, 37232-7610
Pfizer Investigational Site Completed
Smyrna, Tennessee, United States, 37167
United States, Texas
Pfizer Investigational Site Recruiting
Dallas, Texas, United States, 75235
Pfizer Investigational Site Recruiting
Dallas, Texas, United States, 75232
Pfizer Investigational Site Recruiting
Dallas, Texas, United States, 75390
Pfizer Investigational Site Recruiting
Houston, Texas, United States, 77030
United States, Washington
Pfizer Investigational Site Recruiting
Seattle, Washington, United States, 98195
Pfizer Investigational Site Completed
Seattle, Washington, United States, 98122
Pfizer Investigational Site Recruiting
Seattle, Washington, United States, 98109
Pfizer Investigational Site Completed
Seattle, Washington, United States, 98104
Australia, New South Wales
Pfizer Investigational Site Recruiting
Camperdown, New South Wales, Australia, 2050
Australia, South Australia
Pfizer Investigational Site Completed
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Pfizer Investigational Site Recruiting
East Melbourne, Victoria, Australia, 3002
Australia, Western Australia
Pfizer Investigational Site Terminated
Nedlands, Western Australia, Australia, 6009
Brazil
Pfizer Investigational Site Recruiting
Salvador, BA, Brazil, 40170-110
Pfizer Investigational Site Completed
Rio de Janeiro, RJ, Brazil, 20231 -050
Pfizer Investigational Site Terminated
Ijui, RS, Brazil, 98700-000
Pfizer Investigational Site Recruiting
Porto Alegre, RS, Brazil, 90050-170
Pfizer Investigational Site Recruiting
Porto Alegre, RS, Brazil, 90610-000
Pfizer Investigational Site Terminated
Jau, Sao Paulo, Brazil, 17210-120
Pfizer Investigational Site Completed
Barretos, SP, Brazil, 14784-400
Pfizer Investigational Site Completed
Sao Paulo, SP, Brazil, 01246-000
Pfizer Investigational Site Terminated
Sao Paulo, SP, Brazil, 01509-900
Bulgaria
Pfizer Investigational Site Active, not recruiting
Sofia, Bulgaria, 1527
Pfizer Investigational Site Terminated
Sofia, Bulgaria, 1756
Pfizer Investigational Site Completed
Sofia, Bulgaria, 1606
Pfizer Investigational Site Terminated
Varna, Bulgaria, 9002
Canada, Alberta
Pfizer Investigational Site Terminated
Calgary, Alberta, Canada, T2S 3C3
Pfizer Investigational Site Terminated
Calgary, Alberta, Canada, T2N 4N2
Pfizer Investigational Site Terminated
Calgary, Alberta, Canada, T2V 2C4
Pfizer Investigational Site Completed
Edmonton, Alberta, Canada, T6G 1Z2
Canada, New Brunswick
Pfizer Investigational Site Terminated
Moncton, New Brunswick, Canada, E1C 8X3
Pfizer Investigational Site Terminated
Moncton, New Brunswick, Canada, E1C 2Z3
Canada, Ontario
Pfizer Investigational Site Recruiting
Oshawa, Ontario, Canada, L1J 8N8
Pfizer Investigational Site Recruiting
Oshawa, Ontario, Canada, L1G 2B9
Pfizer Investigational Site Completed
Ottawa, Ontario, Canada, K1H 8L6
Canada, Quebec
Pfizer Investigational Site Terminated
Montreal, Quebec, Canada, H3T 1E2
Pfizer Investigational Site Terminated
Montreal, Quebec, Canada, H3G 1A4
Pfizer Investigational Site Terminated
Montreal, Quebec, Canada, H3A 1A1
Pfizer Investigational Site Terminated
Montreal, Quebec, Canada, H2L 4M1
Pfizer Investigational Site Terminated
Montreal, Quebec, Canada, H3T 1M5
China, Jiangsu
Pfizer Investigational Site Recruiting
Nanjing, Jiangsu, China, 210002
China
Pfizer Investigational Site Recruiting
Beijing, China, 100071
Pfizer Investigational Site Recruiting
Beijing, China, 100021
Pfizer Investigational Site Recruiting
Guangzhou, China, 510060
Pfizer Investigational Site Recruiting
Guangzhou, China, 510080
Pfizer Investigational Site Recruiting
Shanghai, China, 200433
Pfizer Investigational Site Recruiting
Shanghai, China, 200032
Pfizer Investigational Site Recruiting
Shanghai, China, 200030
France
Pfizer Investigational Site Completed
Caen Cedex 05, France, 14076
Pfizer Investigational Site Recruiting
Dijon, France, 21079
Pfizer Investigational Site Recruiting
Grenoble Cedex 09, France, 38043
Pfizer Investigational Site Recruiting
Marseille Cedex 20, France, 13915
Pfizer Investigational Site Completed
NICE Cedex 2, France, 06189
Pfizer Investigational Site Completed
Paris Cedex 14, France, 75679
Pfizer Investigational Site Recruiting
Paris cedex 20, France, 75970
Pfizer Investigational Site Completed
St Herblain Cedex, France, 44805
Pfizer Investigational Site Recruiting
Villejuif, France, 94805
Germany
Pfizer Investigational Site Recruiting
Dresden, Germany, 01307
Pfizer Investigational Site Recruiting
Essen, Germany, 45122
Pfizer Investigational Site Recruiting
Grosshansdorf, Germany, 22927
Pfizer Investigational Site Completed
Hamburg, Germany, 22527
Pfizer Investigational Site Recruiting
Heidelberg, Germany, 69126
Pfizer Investigational Site Recruiting
Karlsruhe, Germany, 76137
Pfizer Investigational Site Completed
Koeln, Germany, 50937
Pfizer Investigational Site Recruiting
Muenchen, Germany, 80336
Pfizer Investigational Site Recruiting
Oldenburg, Germany, 26121
Pfizer Investigational Site Recruiting
Wiesbaden, Germany, 65199
Greece
Pfizer Investigational Site Recruiting
Heraklion, Crete, Greece, 71110
Pfizer Investigational Site Terminated
Exohi, Thessaloniki, Greece, 57010
Pfizer Investigational Site Completed
Athens, Greece, 11527
Hong Kong
Pfizer Investigational Site Completed
Pokfulam, Hong Kong
Pfizer Investigational Site Completed
Shatin, New Territories, Hong Kong
Pfizer Investigational Site Recruiting
Tuen Mun, New Territories, Hong Kong
Hungary
Pfizer Investigational Site Terminated
Budapest, Hungary, 1125
Pfizer Investigational Site Completed
Budapest, Hungary, 1121
Pfizer Investigational Site Completed
Debrecen, Hungary, 4032
Pfizer Investigational Site Terminated
Farkasgyepu, Hungary, 8582
Pfizer Investigational Site Terminated
Szekesfehervar, Hungary, 8000
Pfizer Investigational Site Terminated
Torokbalint, Hungary, 2045
Ireland
Pfizer Investigational Site Recruiting
Dublin 8, Ireland
Pfizer Investigational Site Terminated
Galway, Ireland
Italy
Pfizer Investigational Site Completed
Avellino, Italy, 83100
Pfizer Investigational Site Recruiting
Firenze, Italy, 50139
Pfizer Investigational Site Terminated
Genova, Italy, 16132
Pfizer Investigational Site Terminated
Lido di Camaiore (LU), Italy, 55043
Pfizer Investigational Site Recruiting
Lucca, Italy, 55100
Pfizer Investigational Site Recruiting
Milano, Italy, 20141
Pfizer Investigational Site Recruiting
Milano, Italy, 20132
Pfizer Investigational Site Completed
Milano, Italy, 20162
Pfizer Investigational Site Recruiting
Monza, Italy, 20052
Pfizer Investigational Site Recruiting
Orbassano (TO), Italy, 10043
Pfizer Investigational Site Recruiting
Perugia, Italy, 06132
Pfizer Investigational Site Active, not recruiting
Roma, Italy, 00152
Pfizer Investigational Site Terminated
Torino, Italy, 10126
Japan
Pfizer Investigational Site Recruiting
Nagoya, Aichi, Japan
Pfizer Investigational Site Recruiting
Kashiwa, Chiba, Japan
Pfizer Investigational Site Recruiting
Sapporo, Hokkaido, Japan
Pfizer Investigational Site Recruiting
Akashi, Hyogo, Japan
Pfizer Investigational Site Recruiting
Okayama-city, Okayama, Japan
Pfizer Investigational Site Recruiting
Osakasayama-shi, Osaka, Japan
Pfizer Investigational Site Recruiting
Sunto-gun, Shizuoka, Japan
Pfizer Investigational Site Recruiting
Chuo-ku, Tokyo, Japan
Pfizer Investigational Site Recruiting
Fukuoka, Japan
Pfizer Investigational Site Completed
Tokyo, Japan
Korea, Republic of
Pfizer Investigational Site Recruiting
Gyeonggi-do, Korea, Republic of, 410-769
Pfizer Investigational Site Recruiting
Seoul, Korea, Republic of, 110-744
Pfizer Investigational Site Recruiting
Seoul, Korea, Republic of, 135-710
Netherlands
Pfizer Investigational Site Recruiting
Groningen, Netherlands, 9713 GZ
Poland
Pfizer Investigational Site Recruiting
Gdansk, Poland, 80-952
Pfizer Investigational Site Recruiting
Olsztyn, Poland, 10-357
Pfizer Investigational Site Terminated
Poznan, Poland, 60-569
Russian Federation
Pfizer Investigational Site Terminated
Kazan, Russian Federation, 420029
Pfizer Investigational Site Terminated
Moscow, Russian Federation, 115478
Pfizer Investigational Site Completed
Saint-Petersburg, Russian Federation, 197089
Pfizer Investigational Site Recruiting
Saint-Petersburg, Russian Federation, 198255
Pfizer Investigational Site Completed
Saint-Petersburg, Russian Federation, 197022
Pfizer Investigational Site Recruiting
St. Petersburg, Russian Federation, 197022
Spain
Pfizer Investigational Site Completed
Oviedo, Asturias, Spain, 33006
Pfizer Investigational Site Recruiting
Badalona, Barcelona, Spain, 08916
Pfizer Investigational Site Recruiting
L'hospitalet de Llobregat, Barcelona, Spain, 08907
Pfizer Investigational Site Completed
Sabadell, Barcelona, Spain, 08208
Pfizer Investigational Site Completed
Pamplona, Navarra, Spain, 31008
Pfizer Investigational Site Recruiting
A Coruña, Spain, 15006
Pfizer Investigational Site Completed
Barcelona, Spain, 08035
Pfizer Investigational Site Recruiting
Barcelona, Spain, 08003
Pfizer Investigational Site Recruiting
Madrid, Spain, 28046
Pfizer Investigational Site Terminated
Santander, Spain, 39008
Pfizer Investigational Site Terminated
Sevilla, Spain, 41013
Sweden
Pfizer Investigational Site Recruiting
Stockholm, Sweden, 171 76
Taiwan
Pfizer Investigational Site Recruiting
Tainan, Taiwan, 704
Pfizer Investigational Site Completed
Taipei, Taiwan, 112
Pfizer Investigational Site Recruiting
Taipei, Taiwan, 100
United Kingdom
Pfizer Investigational Site Completed
Headington, Oxford, United Kingdom, OX3 7LJ
Pfizer Investigational Site Completed
Sutton, Surrey, United Kingdom, SM2 5PT
Pfizer Investigational Site Completed
Eastleigh, United Kingdom, SO53 2DW
Pfizer Investigational Site Recruiting
London, United Kingdom, SE1 9RT
Pfizer Investigational Site Completed
London, United Kingdom, NW3 2QG
Pfizer Investigational Site Completed
London, United Kingdom, SW3 6JJ
Pfizer Investigational Site Recruiting
Manchester, United Kingdom, M20 4BX
Pfizer Investigational Site Completed
Southampton, United Kingdom, SO16 6YD
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00932451     History of Changes
Other Study ID Numbers: A8081005
Study First Received: June 30, 2009
Last Updated: September 9, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Lung Neoplasms ALK gene Crizotinib

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Crizotinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 19, 2014